Casticin suppresses self-renewal and invasion of lung cancer stem-like cells from A549 cells through down-regulation of pAkt

Acta Biochimica et Biophysica Sinica

Volumn 46, Issue 1, 2014, Pages 15-21

  Liu, Fei ^a   Cao, Xiaozheng ^a   Liu, Zhihong ^b   Guo, Hui ^b   Ren, Kaiqun ^a   Quan, Meifang ^a   Zhou, Yuan ^a   Xiang, Honglin ^a   Cao, Jianguo ^a  

^a HUNAN NORMAL UNIVERSITY   (China)

^b HUNAN CANCER HOSPITAL   (China)

Author keywords

cancer stem cells; casticin; lung cancer; pAkt; therapeutic action

Indexed keywords

CASTICIN; FLAVONOID; PROTEIN KINASE B;

ARTICLE; BIOSYNTHESIS; CANCER STEM CELL; DOWN REGULATION; DRUG EFFECT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PAKT; PHOSPHORYLATION; THERAPY; TUMOR CELL LINE; TUMOR INVASION;

CANCER STEM CELLS; CASTICIN; LUNG CANCER; PAKT; THERAPEUTIC ACTION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DOWN-REGULATION; FLAVONOIDS; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84891363210     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt123     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics 2010. CA Cancer J Clin 2010, 60: 277-300.
2. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55: 74-108.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ. Cancer statistics 2006. CA Cancer J Clin 2006, 56: 106-130.
4. Qiu X, Wang Z, Li Y, Miao Y, Ren Y and Luan Y. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett 2012, 323: 161-170.
5. Beier F, Beier CP, Aschenbrenner I, Hildebrandt GC, Brummendorf TH and Beier D. Identification of CD133(-)/telomerase(low) progenitor cells in glioblastoma-derived cancer stem cell lines. Cell Mol Neurobiol 2011, 31: 337-343.
6. Shakhova O and Sommer L. Testing the cancer stem cell hypothesis in melanoma: the clinics will tell. Cancer Lett 2013, 338: 74-81.
7. Pandey PR, Xing F, Sharma S, Watabe M, Pai SK, Iiizumi-Gairani M and Fukuda K, et al. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene 2013, 32: 5111-5122.
8. Normolle DP, Donnenberg VS and Donnenberg AD. Statistical classification of multivariate flow cytometry data analyzed by manual gating: stem, progenitor, and epithelial marker expression in nonsmall cell lung cancer and normal lung. Cytometry A 2013, 83: 150-160.
9. Wang S, Xu ZY, Wang LF and Su W. CD133 cancer stem cells in lung cancer. Front Biosci (Landmark Ed) 2013, 18: 447-453.
10. Zhou L, Wei X, Cheng L, Tian J and Jiang JJ. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope 2007, 117: 455-460.
11. Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R and Li J, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol 2011, 11: 71.
12. Karimi-Busheri F, Zadorozhny V, Li T, Lin H, Shawler DL and Fakhrai H. Pivotal role of CD38 biomarker in combination with CD24, EpCAM, and ALDH for identification of H460 derived lung cancer stem cells. J Stem Cells 2011, 6: 9-20.
13. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH and Lin TY, et al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 2013, 328: 144-151.
14. Ho MM, Ng AV, Lam S and Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007, 67: 4827-4833.
15. Ono M, Yanaka T, Yamamoto M, Ito Y and Nohara T. New diterpenes and norditerpenes from the fruits of Vitex rotundifolia. J Nat Prod 2002, 65: 537-541.
16. Chen D, Cao J, Tian L, Liu F and Sheng X. Induction of apoptosis by casticin in cervical cancer cells through reactive oxygen species-mediated mitochondrial signaling pathways. Oncol Rep 2011, 26: 1287-1294.
17. Righeschi C, Eichhorn T, Karioti A, Bilia AR and Efferth T. Microarray-based mRNA expression profiling of leukemia cells treated with the flavon-oid, casticin. Cancer Genom Proteom 2012, 9: 143-151.
18. Shen JK, Du HP, Yang M, Wang YG and Jin J. Casticin induces leukemic cell death through apoptosis and mitotic catastrophe. Ann Hematol 2009, 88: 743-752.
19. Tang SY, Zhong MZ, Yuan GJ, Hou SP, Yin LL, Jiang H and Yu Z. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells. Oncol Rep 2013, 29: 474-480.
20. Yang J, Yang Y, Tian L, Sheng XF, Liu F and Cao JG. Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. World J Gastroenterol 2011, 17: 4298-4307.
21. Kobayakawa J, Sato-Nishimori F, Moriyasu M and Matsukawa Y. G2-M arrest and antimitotic activity mediated by casticin, a flavonoid isolated from Viticis Fructus (Vitex rotundifolia Linne fil.). Cancer Lett 2004, 208: 59-64.
22. Haidara K, Zamir L, Shi QW and Batist G. The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action. Cancer Lett 2006, 242: 180-190.
23. Feng X, Zhou Q, Liu C and Tao ML. Drug screening study using glioma stem-like cells. Mol Med Rep 2012, 6: 1117-1120.
24. Setoguchi T, Taga T and Kondo T. Cancer stem cells persist in many cancer cell lines. Cell cycle 2004, 3: 414-415.
25. Tirino V, Camerlingo R, Bifulco K, Irollo E, Montella R, Paino F and Sessa G, et al. TGF-beta1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133 A549 cell fraction. Cell Death Dis 2013, 4: e620.
26. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J and Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010, 126: 950-958.
27. Wu S, Yu L, Wang D, Zhou L, Cheng Z, Chai D and Ma L, et al. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC cancer 2012, 12: 535.
28. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L and Pratesi G, et al. Highly tumorigenic lung cancer CD133 cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009, 106: 16281-16286.
29. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD and Fink LM, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PloS One 2010, 5: e14062.
30. Zhang HZ, Lin XG, Hua P, Wang M, Ao X, Xiong LH and Wu C, et al. The study of the tumor stem cell properties of CD133 CD44 cells in the human lung adenocarcinoma cell line A549. Cell Mol Biol 2010, 56(Suppl): OL1350-OL1358.
31. Sapkota D, Bruland O, Costea DE, Haugen H, Vasstrand EN and Ibrahim SO. S100A14 regulates the invasive potential of oral squamous cell carcinoma derived cell-lines in vitro by modulating expression of matrix metalloproteinases, MMP1 and MMP9. Eur J Cancer 2011, 47: 600-610.
32. Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S and Chellappan SP. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 2012, 11: 73.
33. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C and Schultz PG, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009, 106: 268-273.
34. Moon SH, Kim DK, Cha Y, Jeon I, Song J and Park KS. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int J Oncol 2013, 42: 921-928.
35. Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y and Zhao L, et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PloS One 2012, 7: e39520.
36. Li J and Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011, 11: 49.
37. Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, Funahashi H and Sato M, et al. Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig Dis Sci 2007, 52: 2292-2300.
38. Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R and Lilly MB. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochem Pharmacol 2006, 72: 1257-1267.
39. Song G, Ouyang G, Mao Y, Ming Y, Bao S and Hu T. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med 2009, 13: 1706-1718.
40. Katoh M. Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med 2013, 32: 763-767.